Warfarin Sensitivity Study Results Update on Proposed Issue of American Depositary Shares
LONDON--(BUSINESS WIRE)--Oct 31, 2008 - Osmetech plc (LSE:OMH), the international molecular diagnostics company announces that Dr. Charles S. Eby, M.D., Associate Professor at the Washington University in St. Louis School of Medicine has presented the results of an evaluation performed in his laboratory of Osmetech's Warfarin Sensitivity Test on the eSensor(R) XT-8 instrument at the annual meeting of the Association for Molecular Pathology (AMP) in Texas, US. The results of this evaluation were outstanding, with 100% accuracy and reproducibility for the 440 sample calls made. The tests provided results within 4 hours beginning with genomic DNA, with the random access capability of the System allowing multiple samples to be processed as and when required.
Dr. Eby also presented an overview of pharmacogenetic testing for warfarin sensitivity, including plans for a prospective, multi-center study of pharmacogenetic-based warfarin dosing sponsored by the National Heart, Lung and Blood Institute.
James White, Chief Executive, Osmetech plc, said:
"We are delighted that the excellent clinical trials results submitted to the FDA for the clearance of our Warfarin Sensitivity test are being replicated in the field. In addition to high levels of accuracy, sensitivity and reliability from the results from Dr Eby's study, the eSensor XT-8 System has enabled testing to be performed with a minimal number of manual steps and a rapid turnaround time on an easy to use, small instrument with random access capabilities. The excellent data quality and user friendly attributes of the recently launched eSensor XT-8 System are helping to increase instrument placements which will benefit further from additional tests scheduled for launch including Cystic Fibrosis, CYP450 2C9 drug metabolism, venous thrombosis (Factor II, Factor V Leiden and MTHFR) and the recently in-licensed Qiagen RESPLEX II respiratory pathogen assay."
Proposed issue of American Depositary Shares ("ADSs")
Osmetech continues to progress the proposed issue of ADSs in challenging market conditions. A further announcement will be made in due course.
James White, Chief Executive Officer
+1(626) 463 2000
Matthew Moth, Mark Way
+44 (0) 207 593 4000
Posted: October 2008